Dexcom (DXCM) Capital Expenditures (2010 - 2026)

Dexcom (DXCM) has 17 years of Capital Expenditures data on file, last reported at $76.6 million in Q1 2026.

• Quarterly Capital Expenditures fell 11.95% year-over-year to $76.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $353.1 million (down 9.21% YoY) and the FY2025 annual result came in at $363.5 million, up 1.31% from the prior year.
• Capital Expenditures fell to $76.6 million in Q1 2026 per DXCM's latest filing, from $101.9 million in the prior quarter.
• Across five years, Capital Expenditures topped out at $124.6 million in Q4 2024 and bottomed at $50.4 million in Q3 2023.
• The 5-year median for Capital Expenditures is $80.5 million (2025), against an average of $82.4 million.
• The widest annual swing landed in 2023, when Capital Expenditures sank 53.42%; it then jumped 137.33% in 2024.
• Tracing DXCM's Capital Expenditures over 5 years: stood at $63.5 million in 2022, then fell by 17.32% to $52.5 million in 2023, then jumped by 137.33% to $124.6 million in 2024, then dropped by 18.22% to $101.9 million in 2025, then fell by 24.83% to $76.6 million in 2026.
• Per Business Quant, the three latest DXCM Capital Expenditures figures stand at $76.6 million (Q1 2026), $101.9 million (Q4 2025), and $80.5 million (Q3 2025).

Peer Comparison